Pharmacokinetic Study of Therapeutic Plasma Exchange

N/ANot Yet RecruitingNCT07756242

University of Chicago15 enrolled

Overview

The purpose of this study is to characterize the pharmacokinetics of one or more ICIs during and after TPE/PLEX in patients with severe irAEs.

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy across multiple tumor types; however, their mechanism of action-releasing immune inhibition-inevitably predisposes patients to immune-related adverse events (irAEs). These toxicities occur in up to 74% of patients treated with PD-(L)1 inhibitors and in more than 90% of those receiving combination therapy, with grade 3-5 events in 14-55% of cases depending on regimen and tumor type. Immune-related adverse events caused by ICIs often present with a spectrum of clinical manifestations that closely resemble primary autoimmune diseases affecting multiple organ systems, including the skin, gastrointestinal tract, liver, lung, and nervous system. Therapeutic plasma exchange is an established therapeutic procedure in selected immune-mediated diseases where rapid removal of circulating pathogenic material is clinically relevant (13). In these settings, TPE/PLEX can remove circulating antibodies, immune complexes, complement-related factors, inflammatory mediators, and therapeutic monoclonal antibodies. These precedents support the biologic rationale for considering TPE/PLEX in selected severe irAEs when treating clinicians believe that removal of circulating ICI and/or soluble immune mediators may be clinically appropriate. Immune-related adverse events are an acceptable indication for TPE/PLEX, and the procedure may be considered based on individual patient circumstances and treating-team judgment. The purpose of this small, single-arm, open-label Phase 1 pharmacokinetic study is to characterize ICI concentrations during and after TPE in patients with severe irAEs. Timed PK blood samples will be collected during and after TPE/PLEX according to the study PK sampling plan. Clinically relevant information will be collected from participant's medical record throughout the study.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Immune-related Adverse Event

Interventions

Spectra Optia Apheresis SystemDEVICE

Therapeutic plasma exchange (using the Spectra Optia Apheresis System) will be done according to standard of care.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults ≥ 18 years of age * Diagnosis of any malignancy. * Receiving or recently received an immune checkpoint inhibitor, including anti-PD-1, anti-PD-L1, anti-CTLA-4, or combination ICI therapy. Eligible agents may include, but are not limited to, pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab, cemiplimab, dostarlimab, and ipilimumab. * Received an ICI within 12 weeks prior to planned enrollment, or within a timeframe considered appropriate by the PI for PK evaluation based on the specific ICI agent, dosing history, and assay feasibility. * Suspected or confirmed severe or clinically significant immune-related adverse event for which the treating clinical team considers TPE/PLEX clinically appropriate. * Planned to undergo or currently undergoing TPE/PLEX at the University of Chicago Medicine. * Approval from the patient's primary clinical service for study participation. * Able to provide written informed consent, or has a legally authorized representative able to provide consent if permitted by the IRB-approved consent process. * In the opinion of the treating team and study team, PK blood sample collection can be performed without delaying or interfering with clinically indicated care. Exclusion Criteria: * No prior exposure to an immune checkpoint inhibitor. * TPE/PLEX is being performed for an indication unrelated to a suspected or confirmed ICI-associated immune-related adverse event. * Inability to provide informed consent and no legally authorized representative is available, if applicable. * PK blood sample collection is not feasible without delaying, altering, or interfering with clinically indicated care. * Any condition that, in the opinion of the investigator or treating team, would make participation in the research procedures unsafe or inappropriate.

Locations (1)

The University of Chicago

Chicago, Illinois, United States

Outcomes

Primary Outcomes

Change in circulating ICI concentration during and after TPE/PLEX

This will be measured by ICI concentration before and after TPE/PLEX sessions when paired samples are available, Percent change in ICI concentration from pre- to post-TPE/PLEX, and ICI concentration-time profiles across available PK sampling time points

Time frame: Baseline to Day 90

Secondary Outcomes

Assess the feasibility of conducting a small PK-focused Phase 1 study of TPE/PLEX in patients with severe irAEs.

This will be measured by the Proportion of eligible patients successfully identified and approached, approached patients who consent to study participation, enrolled patients who undergo at least one TPE/PLEX session, enrolled patients with at least one evaluable PK sample, enrolled patients with paired pre-/post-TPE/PLEX PK samples

Time frame: Baseline to Day 90

Central Contacts

Pankti Reid

CONTACT

(773) 702-1234 pankti.reid@bsd.uchicago.edu

Mohamed Ali

CONTACT

Mohamed.Ali@bsd.uchicago.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.